RESUMO
GLP-1 Receptor Agonists: For Which Patients with Type-2 Diabetes? Abstract: In the last few years, the cardiovascular outcome trials for SGLT-2 inhibitors and GLP-1 receptor agonists showed them to significantly lower the risk of cardiorenal endpoints in patients with type-2 diabetes when compared to other antidiabetics. This effect was independent of concurrent medication. This additional benefit is well established in the case of SGLT-2 inhibitors, leading to increased prescription. Following the current evidence, GLP-1 receptor agonists should also be prescribed early in the treatment course of type 2 diabetes. In patients with very high cardiovascular risk, a combination therapy of a GLP-1 receptor agonist with a SGLT-2 inhibitor is an attractive option.
